Intraperitoneal serous adenocarcinoma: A critical appraisal of three hypotheses on its cause

Piek, Jurgen M.J.; Kenemans, P.; Verheijen, René H.M.

doi:10.1016/j.ajog.2004.02.067

Cited by 107 publications

(69 citation statements)

References 216 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8 Recent studies of women with hereditary mutations in the BRCA1 and BRCA2 genes have reported detecting early carcinomas in the fallopian tube in a significant percentage of cases. Recently, Finch et al described a plausible origin in the fallopian tube for five of their seven cases, in the form of a non-invasive (intraepithelial) carcinoma.…”

Section: Introductionmentioning

confidence: 99%

A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations

Folkins

Jarboe

Saleemuddin

et al. 2008

Gynecologic Oncology

267

197

View full text Add to dashboard Cite

Background-Early serous carcinomas (SCAs) predominate in the fimbria of BRCA+ women. An entity in non-neoplastic mucosa sharing several properties of SCA -the "p53 signature" -has been described in the distal fallopian tube and proposed as a precursor to SCA. This study compared the prevalence of p53 signatures in both ovarian cortical inclusion cysts (CICs) and fallopian tubes from BRCA+ women and explored their relationship.

show abstract

Section: Introductionmentioning

confidence: 99%

A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations

Folkins

Jarboe

Saleemuddin

et al. 2008

Gynecologic Oncology

267

197

View full text Add to dashboard Cite

show abstract

“…Patients with a diagnosis of peritoneal or fallopian tube carcinoma were recruited because they are remarkably similar in their morphology, clinical behaviour and treatment to ovarian cancer (Kosary and Trimble, 2002;Piek et al, 2004). Participants were recruited into the study before commencing a first-line platinum-based chemotherapy regimen, conventionally administered every 3 weeks for six cycles (Adams et al, 1998).…”

Section: Participantsmentioning

confidence: 99%

A longitudinal investigation of psychological morbidity in patients with ovarian cancer

2008

View full text Add to dashboard Cite

Ovarian cancer patients may experience psychological disorders due to the aggressive nature of the illness and treatment. We investigated the presence of psychological disorders longitudinally in women with a new diagnosis of ovarian cancer and the factors that predicted development and maintenance of these disorders. Patients were assessed in a prospective longitudinal study at the beginning of chemotherapy treatment, mid-treatment, end of treatment and 3 months follow-up for depression, anxiety, perceived social support, neuroticism and cognitive strategies to control unwanted thoughts. A total of 121 patients were recruited and 85 patients were assessed at all four time points. Three different longitudinal profiles of anxiety and depression caseness were found: non-cases (never cases), occasional cases (cases on at least one but not all four occasions) and stable cases (cases on all four occasions). Most of the women were occasional cases of anxiety (52%, 44), whereas for depression, the majority of women were non-cases (55%, 47). A subset of patients were stable cases of anxiety (22%, 19). Neuroticism and marital status were significant independent predictors of anxiety caseness profile. Neuroticism and use of anti-depressants were independent predictors of depression caseness profile. Social support was not related to psychological morbidity.

show abstract

“…The purported tissue origins include the ovarian surface epithelium, fallopian tube, and secondary Mü llerian system, with the surface epithelial origin as the dominant theory in this field. 2,3 However, the evidence for each theory is largely circumstantial. Progress in this area is hindered by the advanced stage of this tumor at the time of diagnosis and the absence of specific markers for Mü llerian epithelium.…”

mentioning

confidence: 99%

Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?

et al. 2007

View full text Add to dashboard Cite

PAX2 is a urogenital developmental transcription factor expressed in the Wolffian ducts, developing kidneys, and Mü llerian ducts during embryonic stage. Its function in renal development is well documented and its clinical application in the diagnosis of lesions of renal origin has been reported recently. However, information on its role in the Mü llerian-derived genital tract is sparse. In this study, we investigated the expression of PAX2 in human female genital tract using immunohistochemistry. We demonstrated that PAX2 was expressed specifically in the epithelial cells of fallopian tube, endometrial and endocervical glands, but not in the stromal tissues in these areas. PAX2 was detected in secondary Mü llerian structures in the ovary, such as endometriotic and endosalpingiotic glands and rete ovarii, but not in ovarian surface epithelium, surface epithelium-derived inclusion cysts, stroma, or sex-cord-derived structures such as follicles, oocytes, and corpus luteum. In addition, PAX2 was detected in 67% of ovarian papillary serous carcinomas (N ¼ 36) but rarely in peritoneal malignant mesotheliomas, with two exceptions (N ¼ 54). Interestingly, the two PAX2-positive 'peritoneal malignant mesotheliomas' were from female patients and were positive for estrogen receptor. The significance of expression of PAX2 and estrogen receptor in these cases is under investigation. Taken together, we suggest that PAX2 is a novel Mü llerian-specific epithelial marker when used in proper clinical settings. Identification of PAX2 in the majority of papillary serous carcinomas of the ovary but not in the ovarian surface epithelium or epithelium-derived inclusion cysts suggests that this malignant epithelial tumor may be directly derived from the primary or secondary Mü llerian epithelium in or surrounding the ovary, rather than from the surface epithelium or its derivatives.

show abstract

Intraperitoneal serous adenocarcinoma: A critical appraisal of three hypotheses on its cause

Cited by 107 publications

References 216 publications

A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations

A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations

A longitudinal investigation of psychological morbidity in patients with ovarian cancer

Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?

Contact Info

Product

Resources

About